DISCLAIMER: GOLDINVESTMENTCOMPANIES.COM IS AN AFFILIATED PARTNER FOR GOLDCO PRECIOUS METALS, AUGUSTA PRECIOUS METALS, AND BIRCH GOLD GROUP, PROMOTING THEIR GOLD IRA, GOLD 401K TRANSFER AND BITCOIN IRA SERVICES AND PRODUCTS.
Lobe Sciences (CSE:LOBE,OTCQB: LOBEF) chairman and CEO Philip J. Young discusses his company’s recent acquisition of Altemia and the revenue-generation opportunity that comes with it, allowing Lobe Sciences to fund research and development for orphan drugs.
00:45 Overview of Lobe Sciences
03:46 What is an orphan drug?
05:39 The Value proposition behind the acquisition of Altemia
10:01 Future plans for Altemia
#pharmaceuticals #lifescience #investing
Investing News Network (INN)
Find out more about investing by INN @
Browse our 2023 outlook reports:
Follow us Facebook:
Follow us on Twitter:
The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.